Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature

Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients with center-involving diabetic macular edema (D...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Saedon H, Anand A, Yang YC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
fluocinolone acetonide
ILUVIEN
diabetic macular edema
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/b57e9a38a3f64c3da7e9b3e998795f02
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b57e9a38a3f64c3da7e9b3e998795f02
record_format dspace
spelling oai:doaj.org-article:b57e9a38a3f64c3da7e9b3e998795f022021-12-02T06:36:31ZClinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature1177-5483https://doaj.org/article/b57e9a38a3f64c3da7e9b3e998795f022017-03-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-intravitreal-fluocinolone-acetonide-iluvien-implan-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients with center-involving diabetic macular edema (DME) is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or without adjunctive macular laser treatment. However, a significant proportion of patients have persistent and recurrent edema despite repeated anti-VEGF injections. The fluocinolone acetonide (FA) 190 µg intravitreal implant has been shown in pivotal clinical trials to be efficacious for the treatment of DME and has been approved in many countries for use in patients who have not responded to first-line therapy. In this report, we have collated the latest data from the increasing number of studies to illustrate the pattern of usage of the Iluvien FA implant for DME during the current anti-VEGF era. We have shown that there is now a wealth of published evidence from real-world studies to support the clinical utility of the FA implant in achieving further resolution of edema and improving visual acuity outcomes in this challenging group of patients. Keywords: fluocinolone acetonide, Iluvien, diabetic macular edemaSaedon HAnand AYang YCDove Medical Pressarticlefluocinolone acetonideILUVIENdiabetic macular edemaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 583-590 (2017)
institution DOAJ
collection DOAJ
language EN
topic fluocinolone acetonide
ILUVIEN
diabetic macular edema
Ophthalmology
RE1-994
spellingShingle fluocinolone acetonide
ILUVIEN
diabetic macular edema
Ophthalmology
RE1-994
Saedon H
Anand A
Yang YC
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
description Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients with center-involving diabetic macular edema (DME) is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or without adjunctive macular laser treatment. However, a significant proportion of patients have persistent and recurrent edema despite repeated anti-VEGF injections. The fluocinolone acetonide (FA) 190 µg intravitreal implant has been shown in pivotal clinical trials to be efficacious for the treatment of DME and has been approved in many countries for use in patients who have not responded to first-line therapy. In this report, we have collated the latest data from the increasing number of studies to illustrate the pattern of usage of the Iluvien FA implant for DME during the current anti-VEGF era. We have shown that there is now a wealth of published evidence from real-world studies to support the clinical utility of the FA implant in achieving further resolution of edema and improving visual acuity outcomes in this challenging group of patients. Keywords: fluocinolone acetonide, Iluvien, diabetic macular edema
format article
author Saedon H
Anand A
Yang YC
author_facet Saedon H
Anand A
Yang YC
author_sort Saedon H
title Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
title_short Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
title_full Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
title_fullStr Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
title_full_unstemmed Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
title_sort clinical utility of intravitreal fluocinolone acetonide (iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/b57e9a38a3f64c3da7e9b3e998795f02
work_keys_str_mv AT saedonh clinicalutilityofintravitrealfluocinoloneacetonideiluvienregimplantinthemanagementofpatientswithchronicdiabeticmacularedemaareviewofthecurrentliterature
AT ananda clinicalutilityofintravitrealfluocinoloneacetonideiluvienregimplantinthemanagementofpatientswithchronicdiabeticmacularedemaareviewofthecurrentliterature
AT yangyc clinicalutilityofintravitrealfluocinoloneacetonideiluvienregimplantinthemanagementofpatientswithchronicdiabeticmacularedemaareviewofthecurrentliterature
_version_ 1718399834581368832

Ejemplares similares